BIMEKIZUMAB

bimekizumab 320 mg/2 mL injection, 2 mL pen devices

BIMEKIZUMAB (15112J)

bimekizumab 320 mg/2 mL injection, 2 mL pen devices
15112J
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Continuing treatment

Restriction

Indication: Moderate to severe hidradenitis suppurativa
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 5 DPMQ: $3,395.86 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Bimzelx